Spots Global Cancer Trial Database for Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Axillary Node Dissection w or w/o LVB in Node Positive Breast Cancer Patients

Official Title: A Prospective Randomized Trial of Axillary Node Dissection With or Without Lymphaticovenous Bypass (LVB) in Node Positive Breast Cancer Patients

Study ID: NCT05970107

Conditions

Node-positive Breast Cancer

Interventions

Axillary Lymph Node Dissection

Axillary Reverse Mapping

Lymphaticovenous Bypass

Study Description

Brief Summary: Lymphedema is a devastating complication of breast cancer surgery that decreases the quality of life of up to 40% of breast cancer survivors. Most lymphedema in breast cancer patients is because lymphatics shared between the axilla and the arm are sacrificed during axillary lymph node dissection (ALND) surgery, which removes an average of 15 lymph nodes in node positive patients. CCF's breast cancer plastic microvascular surgeons and breast surgical oncologists have collaborated to refine a surgical technique known as LVB that may be used either as a preventive measure (prophylactic LVB) or as a therapeutic intervention (therapeutic LVB). Lymphatic reconstruction with LVB may be an improvement to the current standard of care for node positive breast cancer patients undergoing ALND.

Detailed Description: